Contineum Therapeutics

Contineum Therapeutics

CTNM· Manufacturing· Fiscal year ends in December

CEO pay in FY2025Stock -22.0% in FY2025

Carmine N. Stengone is the CEO of Contineum Therapeutics and was paid $3.4M in FY2025 (Dec), down 30%.

Pay$100 in the stock at the end of FY24 → $78
CEO pay is from each Contineum Therapeutics proxy. The stock line is the value of $100 put in the stock at the start, from the price change of each fiscal year. Dividends are not in it.

Executives3

See all
  1. 1Carmine N. StengoneFY2025
  2. 2Timothy R. Watkins, M.D., MSc.FY2025
  3. 3Peter T. SloverFY2025

Named executives and their total pay, from the Summary Compensation Table of the latest proxy.

Pay

See all

Contineum Therapeutics paid its 3 named executives $6.8M in total in FY2025 (Dec). CEO Carmine N. Stengone was paid $3.4M of that.

Name
Carmine N. StengonePresident and Chief Executive Officer
Timothy R. Watkins, M.D., MSc.Chief Medical Officer and Head of DevelopmentNot disclosedNot disclosed
Peter T. SloverChief Financial OfficerNot disclosedNot disclosed

of each named executive, from the Summary Compensation Table of each proxy.

Peers

No disclosed peer group

No proxy on file names a pay peer group for Contineum Therapeutics. The peer group comes from the proxy statement, so it shows here when a proxy read has it.

Activity

Filings4

See all
Proxy statementDEF 14AApr 30, 2026FY2025
Annual report10-KMar 5, 2026FY2025
Proxy statementDEF 14AApr 29, 2025FY2024
Annual report10-KMar 6, 2025FY2024
For the press:Download CSVDownload PNGHow to use our data